CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 506 enrolled
Drug / intervention
MK-2060 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05027074
NCT05027074Phase 2Completed
CompareCT.gov

A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis

Merck Sharp & Dohme LLC·interventional·Posted Aug 30, 2021·Updated Feb 11, 2026

In Brief

A Phase 2 clinical trial evaluating MK-2060 and Placebo for End-Stage Renal Disease and 2 related conditions. Completed, enrolled 506 participants across 120 sites in 15 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is that at least one of the MK-2060 doses is superior to placebo in increasing the time to first occurrence of AVG event.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
CountriesArgentina, Australia, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Italy, Portugal, Puerto Rico, Romania, Russia, Sweden, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedAug 30, 2021
Enrollment StartSep 17, 2021
Primary CompletionOct 30, 2024
Study CompletionFeb 13, 2025
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 4.8 years ago

Interventions

MK-2060drug

MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion

Placebodrug

Normal saline administered via IV infusion